DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Single-Dose Pharmacokinetics Study of Tapimycin Injection

Information source: Tri-Service General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Tapimycin (piperacillin 4 g + tazobactam 0.5g) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Tri-Service General Hospital

Official(s) and/or principal investigator(s):
Feng-Yee Chang, Principal Investigator, Affiliation: Tri-Service General Hospital


The purpose of this study is to examine the pharmacokinetic properties of Tapimycin injection (piperacillin 4 g + tazobactam 0. 5 g powder for injection) in healthy volunteers under fasting conditions.

Clinical Details

Official title: A Single-Dose Pharmacokinetics Study of Tapimycin Injection(Piperacillin 4 g + Tazobactam 0.5 g Powder for Injection) Administered Under Fasting Conditions to Healthy Adult Subjects

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: To examine the pharmacokinetic properties


Minimum age: 20 Years. Maximum age: 40 Years. Gender(s): Male.


Inclusion Criteria: 1. Provision of signed written informed consent before enrollment into the study, ability to communicate with the investigators, and to understand and comply with the requirements of the study. 2. Healthy adult male, aged between 20 and 40 years old. 3. Body Mass Index (BMI) between 18. 5 and 25. 4. Physically and mentally healthy subjects as confirmed by an interview, medical history, clinical examination, chest x-ray and electrocardiogram. 5. No significant deviation from normal biochemistry. 6. No significant deviation from normal hematology. 7. No significant deviation from normal urinalysis. Exclusion Criteria: 1. History of drug or alcohol abuse within the past year. 2. Medical history of severe drug allergy or sensitivity to analogous drug. 3. Acute or chronic diseases or having undergone surgery from 4 weeks prior to PeriodI dosing. 4. Any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal pathology. 5. Ongoing peptic ulcer and constipation. 6. Planned vaccination during the time course of the study. 7. Taking any clinical study drug from 3 months prior to Period I dosing. 8. Use of any medication, including herb medicine or vitamins from 4 weeks before the study. 9. Blood donation of more than 500 mL within the past 3 months. 10. A positive Hepatitis B surface antigen or positive Hepatitis C antibody. 11. A positive test for HIV antibody.

Locations and Contacts

Additional Information

Starting date: March 2009
Last updated: June 18, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017